The biology of CD45 and its use as a therapeutic target.
All mature hemopoietic lineage cells, with exclusion of platelets and mature erythrocytes, share the surface expression of a transmembrane phosphatase, the CD45 molecule. It is also present on hemopoietic stem cells and most leukemic clones and therefore presents as an appropriate target for immunotherapy with anti-CD45 antibodies. This short review details the biology of CD45 and its recent targeting for both treatment of malignant disorders and tolerance induction. In particular, the question of potential stem cell depletion for induction of central tolerance or depletion of malignant hemopoietic cells is addressed. Mechanisms underlying the effects downstream of CD45 binding to the cell surface are discussed.
Dahlke
Marc H
MH
Centenary Institute of Cancer Medicine and Cell Biology & University of Sydney, Sydney, Australia. mhdahlke@web.de
Larsen
Stephen R
SR
Rasko
John E J
JE
Schlitt
Hans J
HJ
D000818:Animals; D019070:Cell Lineage; D004912:Erythrocytes / Q000276:immunology / Q000378:metabolism; D019337:Hematologic Neoplasms / Q000628:therapy; D006412:Hematopoietic Stem Cells / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007108:Immune Tolerance; D007167:Immunotherapy; D017493:Leukocyte Common Antigens / Q000096:biosynthesis* / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000276:immunology; D020033:Protein Isoforms; D051381:Rats
D020033:Protein Isoforms; D017493:Leukocyte Common Antigens